Update from SOHO 2020 on follicular lymphoma

During the 2020 Annual Meeting of the Society of Hematologic Oncology (SOHO), the Lymphoma Hub was pleased to speak to Steering Committee member Nathan Fowler, MD Anderson Cancer Center, Houston, US. In this interview he provided an update on follicular lymphoma from the SOHO 2020 Meeting.

Nathan Fowler first outlines the recent advances in the management of patients with newly diagnosed indolent lymphoma. He highlights the superiority in progression-free survival observed in patients receiving obinutuzumab + chemotherapy over rituximab + chemotherapy. He also discusses the results from the RELEVANCE trial, evaluating lenalidomide + rituximab vs rituximab + chemotherapy.

In the relapsed setting, several novel agents have been approved by the FDA in recent years, including PI3K inhibitors, lenalidomide in combination with rituximab, and the first-in-class EZH2 inhibitor, tazemetostat.